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Aims: Less strict glycated hemoglobin (HbA1c) thresholds have been recommended in
older and/or frail type 2 diabetes (T2D) patients than in younger and less frail
patients for initiating hypoglycemic agents since 2011. We aimed to assess trends in
HbA1c thresholds at initiation of a first hypoglycemic agent(s) in T2D patients and
the influence of age and frailty on these trends.
Materials and methods: The groningen initiative to analyze type 2 diabetes treat-
ment (GIANTT) database was used, which includes primary care T2D patients from
the north of the Netherlands. Patients initiating a first non-insulin hypoglycemic
agent(s) between 2008 and 2014 with an HbA1c measurement within 120 days
before initiation were included. The influence of calendar year, age, or frailty and the
interaction between calendar year and age or frailty were assessed using multilevel
regression analyses adjusted for confounders.
Results: We included 4588 patients. The mean HbA1c threshold at treatment initia-
tion was 7.4% up to 2010, decreasing to 7.1% in 2011 and increasing to 7.4% in
2014. This quadratic change over the years was significant (P < 0.001). Patients aged
60 to 79 initiated treatments at lower HbA1c and patients of different frailty at similar
HbA1c levels. The interaction between year and age or frailty was not signifi-
cant (P > 0.05).
Conclusions: HbA1c thresholds at initiation of a first hypoglycemic agent(s) changed
significantly over time, showing a decrease after 2010 and an increase after 2012.
The HbA1c threshold at initiation was not influenced by age or frailty, which is in con-
trast with recommendations for more personalized treatment.
1 | INTRODUCTION
An important goal of type 2 diabetes (T2D) management is reducing the
risk of complications by good control of blood glucose levels. This can be
achieved with lifestyle changes but hypoglycemic agents have to be initi-
ated when glucose control is insufficient. The success of T2D
management is often monitored by regularly testing glycated hemoglobin
(HbA1c) levels, which serve as a measure of chronic hyperglycemia.
1 Sev-
eral studies showed that the HbA1c level at initiation of a first hypoglyce-
mic agent is the main predictor of achieving early glycemic control.2,3
Over the last decade, there have been several changes in treat-
ment recommendations for patients with T2D (Supplementary
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Table 1 in Data S1). At first, achieving HbA1c levels below 7% was rec-
ommended for most patients.4-6 Between 2008 and 2010, a perfor-
mance measure assessing the percentage of patients achieving HbA1c
levels below 7% was introduced in primary care in the Netherlands.7,8
Around 2009, several professional organizations started to advocate
more personalized HbA1c targets, particularly in elderly patients.
9,10
Diabetes guidelines started to recommend personalized HbA1c treat-
ment targets in 2011. This personalization was based on the patients'
age and frailty. From 2011 onwards, guidelines recommended HbA1c
targets ≤7.0% for non-frail patients younger than 70 years and
between 7.0% and 8.5% for many patients older than 70 years with a
longer diabetes duration and/or frail patients9,11-13 (Supplementary
Table 1 in Data S1). These targets are also considered as thresholds
for initiating treatment. The extent to which these recommendations
have led to more personalized initiation of hypoglycemic treatment in
clinical practice is unknown.
The aim of our study was to investigate trends in HbA1c
thresholds at initiation of a first hypoglycemic agent(s) and the
possible impact of more personalized treatment recommendations
for older and frail patients with T2D. Given the introduction of
performance measures and changes in treatment recommenda-
tions, we hypothesized that there would be a decrease in the over-
all mean HbA1c thresholds in the period 2008 to 2014 but that
first hypoglycemic agent(s) would be initiated at higher HbA1c
thresholds in older and frail patients after more personalized tar-
gets were introduced.
2 | MATERIALS AND METHODS
2.1 | Study design and population
This was a repeated cross-sectional dynamic cohort study for the
years 2008 to 2014. We used the data available from the GIANTT
(www.giantt.nl) database, which contains anonymous primary care
electronic medical records data from patients with T2D in the north-
ern part of the Netherlands.
For each calendar year, patients were included if they had a con-
firmed diagnosis of T2D, were 18 years or older, and initiated treat-
ment with a first hypoglycemic agent(s) in that year. This initiation
was defined as a prescription for a non-insulin hypoglycemic agent
(anatomic therapeutic chemical [ATC] classification codes A10B) with-
out a prescription for any hypoglycemic agent in the preceding
365 days. Included patients had to have at least 1 year of history in
the GIANTT database before initiation of hypoglycemic treatment.
We excluded patients without a documented HbA1c level within
120 days before or on the day of treatment initiation. In addition,
patients who had been diagnosed with T2D 10 or more years before
treatment initiation and patients who initiated treatment with three
or more hypoglycemic agents were excluded since it is unlikely that
these patients were true initiators. An approval from the ethics com-
mittee is not needed for studies using anonymous medical records
data in the Netherlands. We obtained an exemption letter from the
University Medical Center Groningen Medical Ethics Review Board
(reference number M19.235285).
2.2 | Outcome variable
The primary outcome was the patient's most recent HbA1c level in the
120 days before or on the day of a first hypoglycemic agent(s)
initiation.
2.3 | Explanatory variables
The following explanatory variables were included: calendar year of
treatment initiation, age or frailty of the patient and the interaction
between calendar year and age or frailty. Age was calculated on
January 1 of the year in which the patient initiated treatment. We cat-
egorized age in four groups (<60 years, 60-69 years, 70-79 years, and
≥ 80 years old) based on the different cut-offs observed among guide-
lines (Supplementary Table 1 in Data S1). Frailty was calculated using
an electronic frailty index (eFI), which is based on International Classi-
fication of Primary Care (ICPC) coded diagnoses.14 We excluded dia-
betes from the eFI, thus focusing on differences in additional frailty. A
higher number for the eFI indicates a higher degree of frailty. Since
there are no validated clinical cut-offs for the eFI, we categorized the
scores in tertiles to compare low, medium, and high frailty patients.
2.4 | Confounders
There are several patient characteristics available in the GIANTT data-
base that can be associated with age or frailty and may affect the pre-
scribers' decision to initiate a hypoglycemic agent. The following were
included to correct for potential confounding: sex, duration of diabe-
tes (0-1 year, 2-3 years, 4-5 years, 6-7 years, 8-9 years), presence of
dyslipidemia (defined as low density lipoproteins [LDL] ≥2.5 mmol/L),
systolic blood pressure level (<140 mm Hg or ≥140 mm Hg), esti-
mated glomerular filtration rate (eGFR; ≤60 mL/min or >60 mL/min),
Key Points
• The HbA1c threshold at initiation of a first hypoglycemic
agent(s) showed a temporary decrease to 7.1% in 2011
and increased to 7.4% in 2014.
• The trend in the HbA1c threshold was not influenced by
the patients' age or frailty, in contrast to recommenda-
tions for more personalized targets.
• Patients under 60 and over 80 years initiated treatment
at significantly higher HbA1c levels than patients aged 60
to 79 years.
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presence of albuminuria (albumin creatinine ratio ≥30 mg/g or albu-
min in 24 hours urine ≥300 mg), body mass index (BMI; <24.9 kg/m2,
25-29.9 kg/m2 or ≥30 kg/m2), blood pressure lowering treatment
(no treatment, 1 class, 2 classes, ≥3 classes), lipid lowering treatment
(no treatment or ≥ 1 classes) and number of all other prescribed
chronic medications at initiation (used as a continuous variable). The
most recent laboratory values available in the year before or 7 days
after initiation were used for these variables. BMI was calculated from
weight and height based on the data in the last 5 years or in the year
after initiation or extracted as provided BMI from the database when
weight and/or height were not available. The eGFR was calculated
from serum creatinine using the Modification of Diet in Renal
Disease-4 equation for the years 2008 and 2009, and using the
Chronic Kidney Disease Epidemiology Collaboration equation from
2010 onwards, since the standard way of calculating eGFR in the
Netherlands changed during the study period.14 In case serum creati-
nine was not available, the eGFR measurement was extracted as pro-
vided in the database. Prescribed chronic medication was assessed in
the 120 days before or on the day of treatment initiation.
2.5 | Missing data
No data for the explanatory variables were missing. When confounders
had less than 20% of missing values, they were imputed using multiple
imputation by chained equation (MICE).15 For albuminuria, more than
20% of patients had a missing value. These patients were assumed as
not having albuminuria, since conducting this test in the study period
was less common in patients without suspected kidney problems.
2.6 | Analyses
Characteristics of included patients were analyzed descriptively per
year. We conducted multilevel regression analyses with a two-level ran-
dom intercept model to account for patients being nested within gen-
eral practices. First, using the empty model that includes only the
outcome variable, we calculated the intraclass correlation coefficient
(ICC). The ICC assesses the proportion of variance attributed to general
practices. Second, we created the trend model by adding the calendar
year and the confounders to the model to assess the overall trend over
the years. We compared linear and non-linear trend models using the
Wald test to choose the best fitting final model. Next, we assessed the
effect of age or frailty on these trends by adding the explanatory vari-
ables and the interaction between calendar year and age or frailty on
HbA1c levels at initiation in this trend model. To assess changes over
time in separate age and frailty groups, additional multilevel analyses
were conducted per subgroup. In these models, the Bonferroni method
was used to correct for multiple testing, with a significance level of
P < 0.0125 when testing for trends per age group and of P < 0.0167
when testing for trends per frailty group.
TABLE 1 Characteristics of patients included in the analysis
(N = 4588)
Number of patients in source population; N
2008 (N = 15 086) 345
2009 (N = 18 130) 536
2010 (N = 20 995) 732
2011 (N = 24 059) 744
2012 (N = 26 319) 781
2013 (N = 27 342) 670
2014 (N = 30 450) 780
Females; N (%) 2289 (50)









Glycated hemoglobin A1c at initiation in %; mean ± SD 7.3 ± 1.1
Fasting glucose; mean ± SDa 8.6 ± 2.2
Diabetes duration; N (%)
0-1 years 1522 (33)
2-3 years 1384 (30)
4-5 years 881 (19)
6-7 years 523 (11)
8-9 years 289 (6)
Systolic blood pressure ≥ 140 mm Hg; N (%)b 2263 (54)




Dyslipidemia; N (%)d 2631 (65)
eGFR ≤ 60 mL/min/1.73 m2; N (%)e 680 (16)
Albuminuria (%)f 52 (1)
Number of chronic medication at initiation; mean ± SD 4.1 ± 2.9
Blood pressure lowering treatment at initiation; N (%)
No treatment 1477 (32)
1 class 1124 (25)
2 classes 1077 (23)
3 or more classes 910 (20)
Treated with a lipid lowering drug; N (%) 2679 (58)
aFasting glucose: 1 170 (25.5%) missing values.
bSystolic blood pressure: 399 (8.7%) missing values.
cBody mass index (BMI): 308 (6.7%) missing values.
dLow-density lipoprotein (LDL) cholesterol: 568 (12.4%) missing values.
eEstimated glomerular filtration rate (eGFR): 430 (9.4%) missing values.
fAlbuminuria: 2353 (51.3%) missing values.
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A sensitivity analysis was conducted in which the eFI was used as
a continuous variable in the final model.
The analyses were conducted in Stata version 14 (Stata Corp.,
College Station, Texas).
3 | RESULTS
We included 4588 patients who initiated a first hypoglycemic agent(s)
between 2008 and 2014 (Table 1). The number of patients in each
calendar year differed, whereas the patient characteristics were simi-
lar over the years (Supplementary Table 2 in Data S1). Around 90% of
patients initiated treatment with metformin (Figure 1). The use of sul-
fonylureas slightly decreased over the years from 8% to 6%, mostly
on the account of the newer medication that became available in this
time period. Complete data were available for 74% of the patients.
3.1 | Trends in HbA1c thresholds
The mean HbA1c level before or at initiation of a first hypoglycemic
agent(s) changed quadratically over the years (β(year) = −0.236, 95% CI –
0.334, −0.138, P < 0.001; β(year2) = 0.021, 95% CI 0.012, 0.030,
P < 0.001; joint p using Wald test <0.001; Figure 2A). A stable HbA1c level
at treatment initiation of around 7.4% was observed between 2008 and
2010. This was followed by a decrease to 7.1% in 2011 and a rise thereaf-
ter to 7.4% in 2014 (Figure 2A, Supplementary Table 2 in Data S1).
Of the total variation in HbA1c level at treatment initiation, 6.4%
was explained by differences between general practices (ICC = 0.064).
3.2 | Age and frailty
Patients between 60 and 79 years initiated treatment at significantly
lower HbA1c levels than younger or older patients (Table 2). The drop
in HbA1c thresholds between 2010 and 2011 was visible in all age
groups, as was the rise after 2012 (Figure 2B). Although some differ-
ences in trends between the age groups can be observed after 2012,
the interaction between age and calendar year was not statistically
significant (Table 2). In the analysis per age group, the HbA1c thresh-
old changed significantly over the years in patients younger than
60 years old (β(year) = −0.407, 95% CI –0.608, −0.205, P < 0.001;
β(year2) = 0.036, 95% CI 0.017, 0.055, P < 0.001; joint p using Wald
test <0.001) and aged 60 to 69 years (β(year) = −0.216, 95% CI –
0.360, −0.072, P = 0.003; β(year2) = 0.019, 95% CI 0.005, 0.033,
P = 0.007; joint P using Wald test =0.008), whereas this trend was not
significant in other two groups.
All frailty groups initiated hypoglycemic treatment at similar
HbA1c thresholds (Figure 2C; Table 2). The interaction between frailty
and calendar year was not significant. In the analysis per frailty group,
the HbA1c threshold changed significantly over the years in the least
frail group (β(year) = −0.345, 95% CI –0.515, −0.176, P < 0.001;
β(year2) = 0.032, 95% CI 0.016, 0.049, P < 0.001; joint P using Wald
test <0.001), but this trend was not significant in the other two
groups. The sensitivity analysis, using frailty index as a continuous var-
iable, showed similar non-significant results (Supplementary Table 3 in
Data S1).
4 | DISCUSSION
The mean HbA1c level at initiation of a first hypoglycemic agent(s)
decreased after 2010 and increased after 2012 until the end of our
study period in 2014. Surprisingly, there were no differences in the
trends for patients of different ages or frailty between 2008
and 2014.
The rising trend in HbA1c level at treatment initiation after 2012
is not in line with our hypothesis, since we expected a decrease in the
overall HbA1c threshold throughout the study period. It is, however, in
line with a recent study conducted in Denmark, which assessed the
trends in pre-treatment HbA1c levels between 2000 and 2017, where












2008 2009 2010 2011 2012 2013 2014
metformin sulfonylureas thiazolidinediones DDP-4 met+SU
met+TZD met+DDP-4 SU+TZD SU+DDP-4
F IGURE 1 Type of first
hypoglycemic agent(s) initiated from
2008 to 2014. DDP-4, dipeptidyl
peptidase-4 inhibitor; met,
metformin; SU, sulfonylurea; TZD,
thiazolidinedione
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thereafter was observed.16 Other studies have looked at trends in
proportions of patients achieving target levels, showing either
increases or non-significant changes over time.17-19 An intriguing find-
ing of our study was that a drop in HbA1c levels was particularly seen
between 2010 and 2011. This may be due to policy changes in the
Netherlands. In 2008, performance measures were introduced as
informative indicators for benchmarking the general practitioners
(GPs) on achieving low targets in diabetes patients. In our study
region, additional education and support was offered around 2010 to
the GPs to improve their performance. We did not expect, however,
that the HbA1c would increase after 2012. This could indicate that the
performance measures and other activities only had a temporary
effect.
Our study showed no differences in HbA1c levels at hypogly-
cemic treatment initiation in patients of different ages. This is not
in line with our hypothesis and recommendations of using higher
HbA1c targets for older T2D patients after 2011 (Supplementary
Table 1). Surprisingly, the youngest and the oldest patients initi-
ated treatment at similar slightly higher HbA1c levels. On the one
hand, this could be due to more delay in diagnosing diabetes in
younger as compared to older patients, who are more actively
monitored. This would lead to higher HbA1c levels at diagnosis and
subsequently at treatment initiation. It has indeed been shown
that the HbA1c levels at diagnosis were higher in younger than in
older patients.20,21 On the other hand, it was found that the time
to initiation of a hypoglycemic agent increased with advancing
age.20,21 Thus, the HbA1c level at treatment initiation can be
higher in younger patients because of a delay in diagnosis, while it
can be higher in older patients because of a delay in treatment ini-
tiation. Interestingly, the HbA1c level at initiation increased after
2012 in all age groups, with this increase being the highest in
patients younger than 60 years. We can only speculate about the
possible explanations. It could be that either the GPs or the
patients prefer to try lifestyle changes for a longer period at a
younger age, leading to higher HbA1c levels when deciding to initi-
ate medication. It could also be that GPs became less strict in all
patients because potential overtreatment for diabetes has been
gaining a lot of attention in the last decade.7
Similar to age, there were no significant differences between
patients with different levels of frailty. Frailty has not been used in
previous analyses of hypoglycemic treatment patterns, however, a
recent study observed that patients with three or more comorbidities
were more likely to have a tighter glycemic control than patients with
no or only one comorbidity.22 We conducted a post-hoc analysis using
the number of chronic medications at initiation as a proxy for frailty
and found that patients receiving less than four (median) chronic med-
ications initiated treatment at significantly higher HbA1c levels when
compared to four or more chronic medications (Supplementary
Figure 1 and Supplementary Table 4 in Data S1). Furthermore, the
observed increase after 2012 particularly in patients prescribed less
medication is again unexpected. These results do not support our
hypothesis that less strict treatment thresholds were applied for frail
patients. A possible explanation could be that frailty measured with
the eFI score—or with the number of chronic medication—is not fully
applicable or fitting in clinical practice. The eFI was comparable to the
Groningen Frailty Index in the previous studies14 but it might not be
in line with the GPs' perception of the patient's status. Also, frailty can

































2008 2009 2010 2011 2012 2013 2014
Year of initiation
<60 years 60-69 years
















2008 2009 2010 2011 2012 2013 2014
Year of initiation
eFI 0 - 0.03 eFI 0.06 - 0.08




F IGURE 2 Mean last glycated haemoglobin A1c (HbA1c) levels
with 95% confidence intervals before/at initiation of the first
hypoglycemic agent(s) from 2008 to 2014 in (a) the whole population,
(b) different age groups and (c) different frailty groups. eFI: electronic
frailty index
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lack of consensus on how best to assess it.23 In addition, specific fac-
tors such as life expectancy, functional dependency, and risk of hypo-
glycemia, which are mentioned in relation to personalized treatment
targets, may contribute more to the prescribers' decisions to initiate
treatment than frailty in general.
Our study provides important insights in prescribing trends and
suggests that trends in initiation of a first hypoglycemic agent(s) may
not be fully in accordance to changes in recommendations towards
more personalized treatment. The lack of differentiation between
patients of different ages and frailty is of concern. The increase in
HbA1c thresholds after 2012 in older patients who do not benefit
from tight control is encouraging but this trend was not observed in
the most frail patients. Moreover, this trend appeared stronger in the
youngest age group, where it is unfavorable and indicates
undertreatment of younger and fit patients for whom the disease is
not well controlled and can lead to preventable complications. Possi-
ble explanations for this observation should be studied further.
Implementing personalized treatment in diabetes may require fur-
ther support. A study conducted in the period 2010 to 2012 in seven
European countries, in which physicians were first trained to set per-
sonalized targets, showed that the targets they set for older patients
only marginally deviated from the traditional HbA1c target of 7%. Nei-
ther age, duration of diabetes, presence of polypharmacy or frailty
had a significant impact on the targets set.24 These results suggest
that only issuing new guidelines or providing a training might not be
enough to implement personalized diabetes treatment in practice. It
has been proposed to offer additional tools or algorithms to support
clinical decision-making, which may help in setting more personalized
targets in practice.25-27
The strength of our study is inclusion of a large number of
patients using real-world data from primary care. It is also a first study
to examine trends in HbA1c level at initiation of a first hypoglycemic
agent(s) and to compare patients of different ages and frailty. Our
study has some limitations. First, the number of GPs included in each
calendar year fluctuates. Since only little variation was explained at
practice level, we do not expect that this affected our conclusions.
Second, approximately 10% of patients initiating hypoglycemic ther-
apy were excluded from our analysis because they initiated treatment
with insulin. Although it is unlikely that these patients were true initia-
tors, other studies have shown similar rates of initial therapy with
insulin in patients with T2D.28,29 Therefore, we conducted a post-hoc
analysis including patients who initiated treatment with insulin, which
revealed similar results (data not shown). Third, the observed time
between diabetes diagnosis and treatment initiation was quite long
for some patients. This could be due to persisting with lifestyle
changes for several years before initiating medication treatment. We
have to acknowledge, however, that some GPs may have included
patients with early stages of diabetes or prediabetes in our cohort.
We therefore conducted another post-hoc analysis including only
patients with diabetes duration of 5 years or less (N = 3412), showing
similar results (data not shown). Finally, we had some missing data but
these were imputed using multiple imputation to reduce possible bias.
Frailty, however, was probably underestimated due to incomplete
coding of ICPC diagnoses in electronic medical records.
TABLE 2 Influence of calendar year
and age or frailty on glycated hemoglobin
A1c (HbA1c) thresholds (multilevel
analysis)
β 95% CI P
AGEa
Calendar year −0.241 −0.338, −0.143 <0.001 <0.001b
Calendar year2 0.021 0.012, 0.031 <0.001
Age <60 years −0.063 −0.187, 0.061 0.320
Age 60–69 years −0.256 −0.374, −0.138 0.000
Age 70-79 years −0.185 −0.301, −0.069 0.002
Age ≥80 years Reference group
Interaction year*age None are significant
FRAILTYc
Calendar year −0.223 −0.321, −0.125 <0.001 <0.001b
Calendar year2 0.020 0.011, 0.030 <0.001
Frailty 0-0.03 −0.005 −0.090, 0.081 0.917
Frailty 0.06-0.08 0.057 −0.021, 0.134 0.151
Frailty 0.11-0.36 Reference group
Interaction year*frailty None are significant
Note: The intraclass correlation coefficient (ICC) calculated from the empty model was 0.064.
aThe age model was adjusted for sex, duration of diabetes, number of chronic medication at initiation,
number of antihypertensive drug classes, systolic blood pressure, lipid lowering therapy, presence of albu-
minuria, presence of dyslipidemia, estimated glomerular filtration rate, and BMI.
bJoint significance of calendar year and calendar year2 using Wald test.
cThe frailty model was adjusted for sex, systolic blood pressure, duration of diabetes, number of antihy-
pertensive drug classes, and lipid lowering therapy.
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In conclusion, the observed HbA1c thresholds at initiation of a
first hypoglycemic agent(s) changed significantly over time, showing a
decrease after 2010 followed by an increase after 2012. This qua-
dratic trend was not influenced by patients' age or frailty, which is in
contrast with changed recommendations for more personalized treat-
ment targets in the study period. More research is needed to deter-
mine factors influencing decisions to initiate or refrain from initiating
hypoglycemic treatment in general practice, particularly for frail
patients. Furthermore, the reasons for initiating diabetes treatment at
increasingly higher HbA1c levels in relatively young patients should be
further investigated.
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